Chronic obstructive pulmonary disease and the risk of cardiovascular diseases by Schneider, Cornelia et al.
RESPIRATORY DISEASES
Chronic obstructive pulmonary disease and the risk
of cardiovascular diseases
Cornelia Schneider • Ulrich Bothner •
Susan S. Jick • Christoph R. Meier
Received: 20 March 2009 / Accepted: 5 February 2010 / Published online: 27 February 2010
 Springer Science+Business Media B.V. 2010
Abstract Previous large epidemiological studies report-
ing on the association between chronic obstructive pul-
monary disease (COPD) and cardiovascular diseases
mainly focussed on prevalent diseases rather than on the
incidence of newly diagnosed cardiovascular outcomes.
We used the UK-based General Practice Research Data-
base (GPRD) to assess the prevalence and incidence of
cardiovascular diseases in COPD patients aged 40–79
between 1995 and 2005, and we randomly matched COPD-
free comparison patients to COPD patients. In nested-case
control analyses, we compared the risks of developing an
incident diagnosis of cardiac arrhythmias, venous throm-
boembolism, myocardial infarction, or stroke between
patients with and without COPD, stratifying the analyses
by COPD-severity, using COPD-treatment as proxy for
disease severity. We identified 35,772 patients with COPD
and the same number of COPD-free patients. Most
cardiovascular diseases were more prevalent among COPD
patients than among the comparison group of COPD-free
patients. The relative risk estimates of developing an
incident diagnosis of cardiac arrhythmia (OR 1.19, 95% CI
0.98–1.43), deep vein thrombosis (OR 1.35, 95% CI 0.97–
1.89), pulmonary embolism (OR 2.51, 95% CI 1.62–3.87),
myocardial infarction (OR 1.40, 95% CI 1.13–1.73), or
stroke (OR 1.13, 95% CI 0.92–1.38), tended to be
increased for patients with COPD as compared to COPD-
free controls. The findings of this large observational study
provide further evidence that patients with COPD are at
increased risk for most cardiovascular diseases.
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Introduction
Chronic obstructive pulmonary disease (COPD) is
increasingly recognized as a respiratory disease with an
important systemic component [1, 2]. Persistent low-level
systemic inflammation is present in COPD, reflected for
example by elevated levels of C-reactive protein [3]. Sys-
temic inflammation has also been associated with athero-
sclerosis, ischemic heart disease and stroke [4].
Cardiovascular events are an important cause of morbidity
and mortality among COPD patients [5, 6]. Apart from a
possible direct association between COPD and adverse
cardiovascular outcomes, COPD therapy with beta-agonists
is of concern [7] due to the potential of increasing the risk
for cardiac arrhythmia and myocardial infarction. In addi-
tion, COPD patients may require treatment with macrolides
and quinolone antibiotics [8] which themselves may also
cause adverse cardiovascular effects, and COPD and car-
diovascular diseases also share smoking as an important
risk factor [9].
Regardless of the underlying mechanism, various stud-
ies indicate an association between COPD and the risk of
cardiovascular diseases [10–12]. According to the ACC/
AHA/ESC 2006 guidelines for the management of patients
with atrial fibrillation, supraventricular arrhythmias are
common in patients with COPD [13], and pulmonary
embolism has frequently been observed during exacerba-
tions of COPD [14, 15]. Patients with COPD who experi-
enced a myocardial infarction were at a twofold increased
risk of dying within one-year after the myocardial infarc-
tion compared to patients without COPD [16], and in
another study COPD patients were at an increased risk of
fatal strokes when compared to COPD-free patients [17]. A
Canadian study based on data from Saskatchewan assessed
the period prevalence of cardiovascular events and inci-
dence of hospitalisations and mortality from cardiovascular
outcomes in COPD patients [18, 19] and a study based on
the Kaiser Permanente Medical Care Program [20] pro-
vided additional information on the incidence of hospital-
isations for cardiovascular outcomes.
In the current study, we quantify the risks of developing
an incident diagnosis of cardiac arrhythmia, myocardial
infarction (MI), deep vein thrombosis (DVT), pulmonary
embolism (PE), stroke or transient ischemic attack (TIA) in
relation to COPD using primary-care data from the United
Kingdom (UK) between 1995 and 2005.
Methods
Data source
We used the UK-based General Practice Research Database
(GPRD) to conduct a follow-up study with a nested case–
control analysis. The GPRD has been described in detail
elsewhere [21]. It is a large primary care database estab-
lished in 1987 which encompasses some five million
patients who are enrolled with selected general practitioners
(GPs) throughout the UK. The General Practitioners (GPs)
who contribute data to the GPRD have been trained to
record medical information in a standard manner and to
supply it anonymously. The recorded information includes
demographics, medical diagnoses, and virtually all drug
prescriptions. The patients enrolled in the GPRD are rep-
resentative of the UK population with respect to age, sex
and geographical distribution [21]. GPRD data have been
previously used for studies involving COPD [22], cardiac
arrhythmia [23], DVT and PE [24], MI [25], and stroke [26].
The GPRD is managed by the Medicines and Healthcare
products Regulatory Agency (MHRA). The study protocol
was approved by the Independent Scientific Advisory
Committee (ISAC) for MHRA database research. The
investigators only had access to anonymized information.
Study population
We identified in the GPRD all patients with a first-time
diagnosis of COPD between January 1, 1995 and December
31, 2005 and who were aged 40-79 years. We excluded
patients with less than 3 years of active recording history
prior to the first COPD diagnosis. In addition, we identified at
random from the GPRD one COPD-free comparison subject
for each COPD patient, matched 1:1 on age (same year of
birth), sex, general practice and calendar time (i.e. on the date
of the first COPD diagnosis of the COPD patient). We applied
the same exclusion criteria to the comparison group as to the
COPD patients. Within this study population we assessed and
compared the prevalence of diagnosed cardiovascular dis-
eases prior to the COPD diagnosis or the corresponding date
in the comparison group. We then excluded all patients from
the COPD group and from the comparison group who had a
recorded history of congestive heart failure, MI, DVT, pul-
monary embolism (PE), stroke, TIA, cardiac arrhythmia,
cancer (except non-melanoma skin cancer), HIV, drug abuse,
or alcoholism prior to the first COPD diagnosis (or the cor-
responding date in the COPD-free group).
Follow-up analysis
We followed all remaining patients from the start of fol-
low-up (i.e. the COPD diagnosis date or the corresponding
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date in the comparison group) and assessed the person time
for each patient until he or she developed an incident
diagnosis of arrhythmia, DVT, PE, MI, stroke/TIA, left the
database, died or reached the end of the study (December
31, 2005), whichever came first. As we excluded patients
with prevalent cardiovascular diseases prior to the start
date both from the COPD and the COPD-free comparison
group, the two groups were no longer of equal size for the
follow-up analysis. We followed each patient up to the first
cardiovascular outcome; if more than one outcome was
recorded during follow-up, the patient was only followed
up to the first endpoint. We estimated incidence rates with
95% confidence intervals (CI) separately for each outcome.
Nested case–control analysis
We conducted nested case–control analyses to further
analyze the impact of COPD severity and various potential
confounders on the risk of developing an outcome of
interest, i.e. arrhythmia, DVT, PE, MI or stroke/TIA. For
this purpose we identified at random for each case with a
study outcome up to 4 control patients from the study
population (i.e. patients with or without COPD) who did
not develop arrhythmia, DVT, PE, MI or stroke/TIA during
follow-up. These controls were matched to cases on age,
sex, practice and index date, i.e. the date when the case had
the incident diagnosis of a cardiovascular outcome of
interest. We compared the prevalence of COPD in patients
with a cardiovascular endpoint and his or her controls using
conditional logistic regression analyses. As a surrogate
marker for COPD disease severity we used COPD treat-
ment, similar to a previous approach published by Soriano
et al. [27]. We therefore categorized COPD patients into
three groups; patients with ‘no treatment’ (as surrogate for
mild COPD), with ‘drug treatment’ (as surrogate for
moderate COPD), defined as having had at least one pre-
scription for short acting anticholinergics, short acting beta
agonists, tiotropium, long acting beta agonists, leukotriene
receptor antagonists, inhaled steroids, and/or xanthines, or
with ‘oxygen treatment’ (as surrogate for severe COPD).
We adjusted the analyses for smoking status (none, current,
past, unknown), body mass index (BMI; \18.5, 18.5–24.9,
25–29.9, 30–60 kg/m2, or unknown), and for a range of
comorbidities and drugs. Arrhythmia analyses are adjusted
for smoking status, hypertension, use of beta agonists,
xanthines, quinolones, macrolides, vitamin K antagonists,
beta blockers, calcium channel blockers, diuretics, cardiac
glycosides and coronary dilatators; PE and DVT analyses
are adjusted for smoking status, BMI, hypertension and
NSAID use; MI analyses are adjusted for smoking status,
BMI, hypertension, hyperlipidemia, diabetes and NSAID
use; Stroke/TIA analyses are adjusted for smoking status,
BMI, hypertension, diabetes and use of aspirin.
Statistical analyses were performed with the statistical
software SAS (release 9.1, SAS Institute, Inc., Cary, NC,
USA)
Case validation
All patients with a recorded first-time diagnosis of cardiac
arrhythmia, PE, DVT, MI or stroke/TIA were identified
using specific disease codes recorded by the GP. We val-
idated potential cases according to the pharmacological
treatment recorded after the cardiovascular diagnosis. In
order to be eligible, cases with DVT or PE had to have
been hospitalised within 30 days after the diagnosis or had
to die within 30 days after the diagnosis, and/or had to start
treatment with heparin, vitamin K antagonists, platelet
aggregation inhibitors, direct thrombin inhibitors or fibri-
nolytic enzymes within 90 (DVT) or 180 (PE) days after
the diagnosis. If potential cases had one or more pre-
scriptions for heparin, vitamin K antagonists, platelet
aggregation inhibitors, direct thrombin inhibitors or fibri-
nolytic enzymes recorded more than 90 days prior to the
DVT diagnosis, the potential case was excluded from the
analysis. Patients with an incident MI diagnosis had to have
been hospitalised within 30 days of the MI diagnosis, or
had to die within 30 days after the diagnosis, and/or they
had to start a new treatment with ACE antagonists, beta
blockers, statins, vitamin K antagonists, platelet aggrega-
tion inhibitors, or aspirin within 90 days after the diagno-
sis. Patients with heart surgery or with prescriptions for
heparin, vitamin K antagonists, platelet aggregation
inhibitors, direct thrombin inhibitors or fibrinolytic
enzymes more than 30 days prior to the diagnosis date
were excluded. Stroke or TIA patients had to be hospita-
lised within 30 days of the stroke diagnosis, had to die
within 30 days after the diagnosis, and/or had to have new
treatment with aspirin, heparin, vitamin K antagonists,
platelet aggregation inhibitors, direct thrombin inhibitors or
fibrinolytic enzymes within 180 days after the diagnosis.
Results
We identified a total of 35,772 patients with a first-time
COPD diagnosis between 1995 and 2005, and the same
number of matched COPD-free patients in the comparison
group. The total study population of 71,544 patients
encompassed slightly more men (51.3%) than women
(48.7%), and 73.3% of the study population were 60 years
of age or older at the time of the first recording of a COPD
diagnosis. With the exception of hypertension, most other
cardiovascular diseases were more prevalent among COPD
patients than among patients in the comparison group prior
to the time of the first COPD diagnosis (or the
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corresponding date in the COPD-free comparison group).
Characteristics of the study population are shown in
Table 1.
After excluding patients with prevalent cardiovascular
diseases, cancer, HIV, alcoholism or drug abuse, we
identified among the remaining study population 1,191
cases with an incident cardiac arrhythmia diagnosis, 136
cases with incident pulmonary embolism, 210 cases with
incident DVT, 511 cases with incident MI, and 598 cases
with an incident stroke/TIA diagnosis. Incidence rates of
all cardiovascular endpoints were higher among COPD
patients than among patients without COPD; the incidence
rate of PE was more than twice as high (12.8/10,000 py
among COPD patients vs. 5.4/10,000 py in the comparison
group). In absolute terms, the incidence rates were highest
for arrhythmia (91.1/10,000 py among COPD patients and
66.7/10,000 py in the comparison group), and lowest for
PE. The various incidence rates, stratified by gender, are
displayed in detail in Table 2.
In order to evaluate the effect of COPD severity on the
risk of developing a study outcome of interest, we con-
ducted a nested case–control analysis, where we stratified
COPD patients according to their treatment pattern into
mild, moderate or severe COPD. The relative risk of
developing arrhythmia overall was similar for patients with
or without COPD (OR 1.19, 95% CI 0.98–1.43), and
COPD severity did not alter the risk estimate substantially.
Table 1 Characteristics of the study population
COPD COPD Free OR (95% CI)*
# % # %
Male 18,361 51.3 18,361 51.3 –
Age groups (years)
40–49 2,432 6.8 2,431 6.8 –
50–59 7,101 19.9 7,105 19.9 –
60–69 12,075 33.8 12,072 33.8 –
[70 14,164 39.6 14,164 39.6 –
Smoking status
Non smoker 7,722 21.6 18,030 50.4 1.00 (ref)
Current smoker 15,472 43.3 6,428 18.0 6.27 (5.99–6.57)
Ex-smoker 9,054 25.3 6,431 18.0 3.65 (3.48–3.83)
Unknown 3,524 9.8 4,883 13.7 1.50 (1.41–1.60)
BMI (kg/m2)
15.0–18.4 1,301 3.6 325 0.9 3.56 (3.14–4.03)
18.5–24.9 12,026 33.6 10,678 29.9 1.00 (ref)
25.0–29.9 9,643 27.0 11,647 32.6 0.74 (0.71–0.76)
30.0–60.0 5,660 15.8 5,690 15.9 0.89 (0.85–0.93)
Unknown 7,142 20.0 7,432 20.8 0.84 (0.80–0.88)
Arrhythmia 2,589 7.2 2,291 6.4 1.15 (1.08–1.21)
CHF 2,991 8.4 1,253 3.5 2.62 (2.44–2.81)
DVT 790 2.2 715 2.0 1.11 (1.00–1.23)
Hypertension 9,782 27.4 11,353 31.7 0.80 (0.77–0.82)
MI/IHD 6,528 18.3 5,561 15.6 1.23 (1.18–1.28)
PE 527 1.5 333 0.9 1.59 (1.39–1.83)
Stroke/TIA 2,454 6.9 2,093 5.9 1.19 (1.12–1.26)
BMI body mass index, ref reference group, CHF congestive heart
failure, CI confidence interval, IHD ischemic heart disease, MI
myocardial infarction, OR odds ratio, PE pulmonary embolism, ref
reference, TIA transient ischemic attack. For all cardiovascular dis-
eases each disease-free status is the referent
* OR from univariate analyses, but adjusted for age, sex, GP and
index date by matching
Table 2 Incidence rates of cardiovascular diseases in COPD and
control patients
# Cases Person
years (py)
IR per
10,000 py
95% CI
Arrhythmia
COPD-Free 563 84435.2 66.7 (61.4–72.4)
Men 288 39532.0 72.9 (64.9–81.7)
Women 275 44903.3 61.2 (54.4–68.9)
COPD 628 68958.5 91.1 (84.3–98.4)
Men 334 32432.2 103.0 (92.6–114.6)
Women 294 36526.2 80.5 (71.8–90.2)
PE
COPD-Free 46 85765.1 5.4 (4.0–7.2)
Men 23 40260.6 5.7 (3.8–8.6)
Women 23 45504.4 5.1 (3.4–7.6)
COPD 90 70233.0 12.8 (10.4–15.8)
Men 48 33258.3 14.4 (10.9–19.1)
Women 42 36974.8 11.4 (8.4–15.4)
DVT
Controls 96 85765.1 11.2 (9.2–13.7)
Men 39 40260.6 9.7 (7.1–13.2)
Women 57 45504.4 12.5 (9.7–16.2)
COPD 114 70233.0 16.2 (13.5–19.5)
Men 53 33258.3 15.9 (12.2–20.8)
Women 61 369774.8 16.5 (12.9–21.2)
MI
COPD-Free 224 85538.9 26.2 (23.0–29.8)
Men 147 39990.9 36.8 (31.3–43.2)
Women 77 45548.0 16.9 (13.5–21.1)
COPD 287 70055.2 41.0 (36.5–46.0)
Men 174 33000.8 52.7 (45.5–61.1)
Women 113 37054.3 30.5 (25.4–36.7)
Stroke/TIA
COPD-Free 298 84586.7 35.2 (31.5–39.5)
Men 165 39554.0 41.7 (35.8–48.6)
Women 133 45032.7 29.5 (24.9–35.0)
COPD 300 69510.2 43.2 (38.6–48.3)
Men 134 32857.9 40.8 (34.5–48.3)
Women 166 36652.2 45.3 (38.9–52.7)
IR incidence rate, CI confidence interval
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The same is true for the association between COPD and the
risk of stroke/TIA with an overall relative risk estimate of
1.13 (95% CI 0.92–1.38) for COPD patients as compared
to patients without COPD. For MI, the relative risk esti-
mate was highest for patients with severe COPD (OR 3.00,
95% CI 1.53–5.86), while the relative risk of PE was
increased across all categories of COPD severity with a
particularly high risk for patients with severe COPD, based
on only 8 cases and 6 controls (OR 7.47, 95% CI 2.35–
23.7). Overall, the risk of DVT was 1.35 (95% CI 0.97–
1.89) for COPD patients compared to COPD-free controls.
The findings for the various cardiovascular outcomes,
stratified by COPD severity, are displayed in Table 3.
In addition to a range of potential confounders, we also
adjusted the model on arrhythmias for use of potentially
arrhythmic drugs (e.g. certain antibiotics) prior to the index
date. In order to test whether use of such drugs may also
play a role in the risk of developing other cardiovascular
outcomes, we also adjusted the analyses on all other car-
diovascular outcomes for use of potentially arrhythmic
drugs, but this did not alter the findings materially (data not
shown).
Discussion
In this large observational study, we explored the associ-
ation between COPD and the risk of developing an incident
diagnosis of cardiac arrhythmia, DVT, PE, MI, or stroke/
TIA. We quantified the prevalence of these diseases prior
to the first COPD diagnosis, and we compared their inci-
dence rates between COPD patients and a matched com-
parison group free of COPD. In general, the findings for the
association between cardiovascular diseases and COPD in
our study are comparable to results from studies in other
health care settings and/or other countries.
Table 3 Case–Control analysis
of the risk of various
cardiovascular diseases
stratified by COPD severity
OR odds ratio, ref reference
value, CI confidence interval, #
number of
a Arrhythmia analyses are
adjusted for smoking status,
hypertension, beta agonist use,
xanthine use, quinolone use,
macrolide use, vitamin K
antagonist use and use of beta
blockers, calcium channel
blockers, diuretics, cardiac
glycosides and coronary
dilatators; PE and DVT analyses
are adjusted for smoking status,
BMI, hypertension and NSAID
use; MI analyses are adjusted
for smoking status, BMI,
hypertension, hyperlipidemia,
diabetes and NSAID use;
Stroke/TIA analyses are
adjusted for smoking status,
BMI, hypertension, aspirin use
and diabetes
# Cases # Controls Crude OR (95% CI) Adjusteda OR (95% CI)
Arrhythmia
No COPD 563 3,116 1.00 (ref) 1.00 (ref)
Any COPD 628 2,418 1.42 (1.25–1.61) 1.19 (0.98–1.43)
Mild 48 191 1.42 (1.01–2.00) 1.64 (1.14–2.34)
Moderate 548 2,146 1.39 (1.22–1.59) 1.07 (0.86–1.32)
Severe 32 81 2.10 (1.36–3.23) 1.29 (0.79–2.11)
PE
No COPD 46 314 1.00 (ref) 1.00 (ref)
Any COPD 90 230 2.57 (1.74–3.78) 2.51 (1.62–3.87)
Mild 7 18 2.61 (1.03–6.64) 3.58 (1.32–9.70)
Moderate 75 206 2.39 (1.60–3.58) 2.23 (1.42–3.50)
Severe 8 6 8.58 (2.88–25.6) 7.47 (2.35–23.7)
DVT
No COPD 96 454 1.00 (ref) 1.00 (ref)
Any COPD 114 386 1.38 (1.02–1.86) 1.35 (0.97–1.89)
Mild 10 26 1.78 (0.84–3.77) 1.73 (0.78–3.80)
Moderate 100 334 1.41 (1.03–1.91) 1.37 (0.97–1.94)
Severe 4 26 0.70 (0.24–2.06) 0.79 (0.26–2.39)
MI
No COPD 224 1,082 1.00 (ref) 1.00 (ref)
Any COPD 287 813 1.70 (1.39–2.06) 1.40 (1.13–1.73)
Mild 33 64 2.43 (1.56–3.81) 1.79 (1.12–2.86)
Moderate 238 726 1.58 (1.29–1.94) 1.30 (1.04–1.62)
Severe 16 23 3.11 (1.62–5.95) 3.00 (1.53–5.86)
Stroke/TIA
No COPD 298 1,256 1.00 (ref) 1.00 (ref)
Any COPD 300 1,004 1.25 (1.05–1.49) 1.13 (0.92–1.38)
Mild 20 66 1.28 (0.77–2.15) 1.22 (0.71–2.09)
Moderate 271 900 1.26 (1.05–1.51) 1.13 (0.92–1.38)
Severe 9 38 0.98 (0.47–2.05) 1.00 (0.47–2.15)
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PE is a relatively rare outcome, but the association
between COPD and PE was rather strong (OR 2.51, 95% CI
1.62–3.87) with incidence rates increased both in men and
women with COPD compared to COPD-free controls. It is
difficult to tell whether this association is a causal one or
possibly the result of some diagnostic bias, since PE has
been reported to be frequently observed during exacerba-
tions of COPD [14, 15]. The authors of a French prospective
cohort study investigated PE in COPD patients with unex-
plained exacerbations and reported a prevalence of PE of
25% [14]. Sidney et al. [20] reported an age-adjusted case
patient rate per 100,000 py for hospitalized PE of 129.4
among COPD patients and a 2.74 (95% CI 1.99–3.76)-fold
increased relative risk of hospitalisation due to PE among
COPD patients compared to control patients, adjusted for
age, gender and cardiovascular risk morbidities. The RR in
women of 2.32 (95% CI 1.58–3.41) is closely similar to the
crude IRR 2.25 (1.38–3.66) which we found, however, their
RR in men was slightly higher than in our analysis. A study
based on Saskatchewan data reported a 5.46 (95% CI 4.25–
7.02)-fold increased relative risk of PE for COPD patients
when compared to control patients [18]. DVT, often pre-
ceding pulmonary embolism, was not associated with a
substantially altered relative COPD risk when compared to
the COPD-free comparison group in our study.
In absolute terms, cardiac arrhythmia was the most fre-
quent cardiovascular outcome observed in our study popu-
lation. COPD patients—both men and women—were
slightly more likely to have an incident arrhythmia diagnosis
recorded than patients without COPD. Part of this associa-
tion might be explained by a higher exposure to arrhyth-
mogenic drugs such as beta agonists, a mainstay in COPD
therapy [7], and quinolone or macrolide antibiotics for bac-
terial infections [8]. Hypoxemia and hypercapnia in COPD
patients may also contribute to an increased risk of cardiac
arrhythmias as they increase the QTc dispersion (QTcD)
[28]. The authors of a Danish study focussed on atrial
fibrillation among COPD patients and observed an increased
risk associated with reduced lung function during a five-year
follow-up [29]. Previously reported baseline prevalences of
arrhythmia in COPD vary; Sidney et al. [20] reported that
4.7% of COPD patients had atrial fibrillation and 2.7% other
arrhythmias, while a study in American Veterans found a
prevalence of arrhythmias of 14.2% [30]. A comparison of
the prevalence of arrhythmias in a Canadian study found an
OR of 1.76 (95% CI 1.64–1.89) when comparing COPD
patients with COPD-free patients. This study did not exclude
patients with a history of cardiovascular events, but the
authors adjusted the analysis for cardiovascular comorbidi-
ties [18]. The authors of another observational study strati-
fied by COPD severity and reported relative risk estimates
associated with various levels of COPD severity ranging
from 0.92 (mild COPD) to 1.27 (severe COPD) [17].
We observed a rather strong association between severe
COPD and the risk of developing an incident MI (OR 3.00,
95% CI 1.53–5.86], after adjusting for smoking, a common
risk factor of COPD and MI. Persistent low-level systemic
inflammation, reflected by increased levels of the C-reac-
tive protein (CRP), is often present in patients with COPD
[3], and increased levels of CRP are associated with an
increased MI risk. Several previous observational studies
have reported an association between COPD and MI [18,
20], while Engstro¨m et al. [31] did not detect an association
between low FEV1 and cardiac events, defined as fatal or
non-fatal MI or death from chronic ischemic heart disease.
The association between COPD and risk of MI was higher
in women than in men, an observation which was also
reported by Sydney et al. [20].
We found only a weak association between COPD and
the risk of stroke/TIA with an OR of 1.13 (95% CI 0.92–
1.38). While the crude incidence rates in men with or
without COPD were closely similar, COPD was associated
with a 1.5-fold increased risk in women. Sidney et al. also
reported a RR of 1.50 (95% CI 1.30–3.41) in women with
COPD. [20] Truelsen et al. [32] explored the association
between reduced lung function and the risk of stroke,
resulting in ORs ranging between 1.00 and 1.38 for FEV1
values below 80% when compared to FEV1 val-
ues C100%. Hozawa et al. [33] did not find a significant
association between airway obstruction and ischemic
stroke. Engstro¨m et al. [31] did not observe a statistically
significantly altered risk when they studied the association
between low FEV1 and stroke. Two other longitudinal
studies found only weak associations between COPD and
stroke [18, 20]. Thus, COPD does not seem to substantially
alter the risk of developing a first-time diagnosis of stroke.
Whether the slightly different findings for MI and stroke/
TIA risks in association with COPD indeed reflect a greater
vulnerability of women, or whether this is due to residual
confounding e.g. by smoking needs further investigation.
Several limitations of our study need to be addressed. As
this study is based on data from the primary-care setting,
there is a possibility that we might have missed some cases
with COPD, especially patients with milder forms of
COPD who have not yet been diagnosed. Thus, our results
only apply to GP-diagnosed COPD diagnoses, and the
same holds true for the cardiovascular outcomes. However,
as most of the cardiovascular outcomes in this study rep-
resent acute and rather severe diseases, we can assume that
few cases with an outcome of interest would have been
missed. We decided a priori to analyze only the first car-
diovascular event during follow-up; the various cardio-
vascular outcomes are highly related to each other and their
treatment and management is similar, thus a first episode of
a cardiovascular outcome materially alters the risk of
developing a second. It would have been desirable to have
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(more) information on potential risk factors for the out-
comes such as immobility, disease severity or socioeco-
nomic status. We assessed COPD severity using medication
as a proxy in the nested case–control analysis, and we
stratified the analyses by this parameter. However, we were
not able to classify the large group of patients with moderate
COPD (i.e. those with some pharmacological treatment) in
more detail with these data. By matching cases and controls
on practice, we controlled to some degree for socioeco-
nomic status, as social deprivation shows a geographical
pattern and therefore people from the same area are more
likely to see the same GP. On the other hand, it is a strength
of the this high-quality data source that it encompassed a
large population with a considerably long follow-up of up to
10 years, and this database has already proven to be of high
validity for studies of COPD and various cardiovascular
outcomes. Another advantage of the GPRD, for example
compared with other settings such as the study from the
Kaiser Permanente Medical Care Program, is the avail-
ability of information on lifestyle factors, in this case par-
ticularly on smoking. Collecting information from different
settings is important as the pattern and the impact of factors,
such as smoking or health care system, may vary.
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